Drug Profile
Fondaparinux sodium oral - Alchemia/Emisphere Technologies
Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Alchemia
- Developer Alchemia; Emisphere Technologies
- Class Anticoagulants; Antithrombotics; Polysaccharides
- Mechanism of Action Factor Xa inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Deep vein thrombosis
Most Recent Events
- 14 Dec 2020 Emisphere Technologies has been acquired by Novo Nordisk
- 19 Mar 2010 Preclinical trials in Deep vein thrombosis in Australia (PO)
- 19 Mar 2010 Preclinical trials in Deep vein thrombosis in USA (PO)